Search results

This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.

Type

NICE guideline

Published

26 February 2021

This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

Type

NICE guideline

Last updated

23 July 2019

This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

Type

NICE guideline

Published

22 January 2020

This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

Type

NICE guideline

Last updated

25 July 2019

This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:

Type

NICE guideline

Published

10 September 2018

This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.

Type

NICE guideline

Published

12 August 2019

This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.

Type

NICE guideline

Published

16 October 2019

This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

Type

NICE guideline

Published

15 January 2019

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

Type

NICE guideline

Published

20 June 2018

This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

Type

NICE guideline

Published

03 October 2018

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Type

Highly specialised technologies guidance

Published

22 May 2019

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Type

Highly specialised technologies guidance

Published

09 October 2019

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Type

Highly specialised technologies guidance

Published

14 August 2019

Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults

Type

Highly specialised technologies guidance

Published

21 October 2020

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Type

Highly specialised technologies guidance

Published

10 October 2018

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Type

Highly specialised technologies guidance

Published

27 November 2019

Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults

Type

Highly specialised technologies guidance

Published

24 February 2021

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

Type

Technology appraisal guidance

Last updated

20 June 2018

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Type

Technology appraisal guidance

Last updated

26 October 2018

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Type

Technology appraisal guidance

Published

08 August 2018

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

08 August 2018

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in

Type

Technology appraisal guidance

Published

08 August 2018

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Type

Technology appraisal guidance

Published

01 August 2018

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

18 July 2018

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

Type

Technology appraisal guidance

Published

04 July 2018

Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

04 July 2018

Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary

Type

Technology appraisal guidance

Published

04 July 2018

Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults

Type

Technology appraisal guidance

Published

07 August 2019

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Type

Technology appraisal guidance

Published

31 July 2019

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Type

Technology appraisal guidance

Published

31 July 2019

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults

Type

Technology appraisal guidance

Published

26 June 2019

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

Type

Technology appraisal guidance

Published

26 June 2019

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (MS) in adults

Type

Technology appraisal guidance

Published

12 June 2019

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell

Type

Technology appraisal guidance

Published

05 June 2019

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma that is intermediate- or poor-risk in

Type

Technology appraisal guidance

Published

15 May 2019

Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults

Type

Technology appraisal guidance

Published

15 May 2019

Evidence-based recommendations on abemaciclib (Verzenios) for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer

Type

Technology appraisal guidance

Published

08 May 2019

Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Type

Technology appraisal guidance

Published

01 May 2019

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults

Type

Technology appraisal guidance

Published

17 April 2019

Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults

Type

Technology appraisal guidance

Published

10 April 2019

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more

Type

Technology appraisal guidance

Published

13 March 2019

Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness

Type

Technology appraisal guidance

Published

07 March 2019

Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma (SEA; elevated levels of eosinophils in blood) in adults

Type

Technology appraisal guidance

Last updated

03 September 2019

Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor

Type

Technology appraisal guidance

Published

27 February 2019

Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Type

Technology appraisal guidance

Published

27 February 2019

Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults

Type

Technology appraisal guidance

Published

27 February 2019

NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence

Type

Technology appraisal guidance

Published

20 February 2019

Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease

Type

Technology appraisal guidance

Published

09 January 2019

Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib

Type

Technology appraisal guidance

Published

09 January 2019

Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of stage III melanoma with lymph node involvement in adults

Type

Technology appraisal guidance

Published

19 December 2018